JP2004502409A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004502409A5 JP2004502409A5 JP2001580185A JP2001580185A JP2004502409A5 JP 2004502409 A5 JP2004502409 A5 JP 2004502409A5 JP 2001580185 A JP2001580185 A JP 2001580185A JP 2001580185 A JP2001580185 A JP 2001580185A JP 2004502409 A5 JP2004502409 A5 JP 2004502409A5
- Authority
- JP
- Japan
- Prior art keywords
- variable region
- ferm
- amino acid
- seq
- acid residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20134400P | 2000-05-02 | 2000-05-02 | |
| PCT/US2001/014151 WO2001083560A1 (en) | 2000-05-02 | 2001-05-02 | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005113535A Division JP3892466B2 (ja) | 2000-05-02 | 2005-04-11 | 腫瘍壊死因子関連アポトーシス誘導性リガンドレセプターに対して選択的な抗体およびそれらの用途 |
| JP2006315093A Division JP2007091749A (ja) | 2000-05-02 | 2006-11-22 | 腫瘍壊死因子関連アポトーシス誘導性リガンドレセプターに対して選択的な抗体およびそれらの用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004502409A JP2004502409A (ja) | 2004-01-29 |
| JP2004502409A5 true JP2004502409A5 (2) | 2007-02-01 |
| JP4156238B2 JP4156238B2 (ja) | 2008-09-24 |
Family
ID=22745456
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001580185A Expired - Lifetime JP4156238B2 (ja) | 2000-05-02 | 2001-05-02 | 腫瘍壊死因子関連アポトーシス誘導性リガンドレセプターについて選択的な抗体、およびそれらの使用 |
| JP2005113535A Expired - Lifetime JP3892466B2 (ja) | 2000-05-02 | 2005-04-11 | 腫瘍壊死因子関連アポトーシス誘導性リガンドレセプターに対して選択的な抗体およびそれらの用途 |
| JP2006315093A Pending JP2007091749A (ja) | 2000-05-02 | 2006-11-22 | 腫瘍壊死因子関連アポトーシス誘導性リガンドレセプターに対して選択的な抗体およびそれらの用途 |
| JP2008194948A Expired - Lifetime JP4575975B2 (ja) | 2000-05-02 | 2008-07-29 | 腫瘍壊死因子関連アポトーシス誘導性リガンドレセプターに対して選択的な抗体およびそれらの用途 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005113535A Expired - Lifetime JP3892466B2 (ja) | 2000-05-02 | 2005-04-11 | 腫瘍壊死因子関連アポトーシス誘導性リガンドレセプターに対して選択的な抗体およびそれらの用途 |
| JP2006315093A Pending JP2007091749A (ja) | 2000-05-02 | 2006-11-22 | 腫瘍壊死因子関連アポトーシス誘導性リガンドレセプターに対して選択的な抗体およびそれらの用途 |
| JP2008194948A Expired - Lifetime JP4575975B2 (ja) | 2000-05-02 | 2008-07-29 | 腫瘍壊死因子関連アポトーシス誘導性リガンドレセプターに対して選択的な抗体およびそれらの用途 |
Country Status (27)
| Country | Link |
|---|---|
| US (6) | US7244429B2 (2) |
| EP (4) | EP2065400B1 (2) |
| JP (4) | JP4156238B2 (2) |
| KR (2) | KR100817967B1 (2) |
| CN (2) | CN101585881B (2) |
| AT (1) | ATE426615T1 (2) |
| AU (2) | AU2001259366B2 (2) |
| BG (3) | BG109275A (2) |
| BR (1) | BR0110547A (2) |
| CA (1) | CA2407965C (2) |
| CY (1) | CY1109179T1 (2) |
| CZ (2) | CZ306996B6 (2) |
| DE (1) | DE60138097D1 (2) |
| DK (1) | DK1287035T3 (2) |
| EE (1) | EE05548B1 (2) |
| ES (1) | ES2323448T3 (2) |
| HU (2) | HU230399B1 (2) |
| IL (1) | IL152605A0 (2) |
| MX (1) | MXPA02010823A (2) |
| NO (2) | NO329843B1 (2) |
| NZ (1) | NZ522881A (2) |
| PL (1) | PL211733B1 (2) |
| PT (1) | PT1287035E (2) |
| RU (1) | RU2298013C2 (2) |
| TW (1) | TWI318983B (2) |
| WO (1) | WO2001083560A1 (2) |
| ZA (1) | ZA200209230B (2) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7528239B1 (en) | 1997-02-13 | 2009-05-05 | Immunex Corporation | Receptor that binds trail |
| JP4330180B2 (ja) | 1997-03-17 | 2009-09-16 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | 死ドメイン含有レセプター５ |
| US6872568B1 (en) | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
| JP2002543151A (ja) * | 1999-05-04 | 2002-12-17 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | 死ドメイン含有レセプター５ |
| TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| US7279160B2 (en) | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
| US7476383B2 (en) | 2000-05-02 | 2009-01-13 | The Uab Research Foundation | Antibody selective for DR4 and uses thereof |
| US20030228309A1 (en) * | 2000-11-08 | 2003-12-11 | Theodora Salcedo | Antibodies that immunospecifically bind to TRAIL receptors |
| US20060062786A1 (en) * | 2000-11-08 | 2006-03-23 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| AU2003222427B8 (en) | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| US8071740B2 (en) | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| US7115717B2 (en) | 2001-05-18 | 2006-10-03 | Kirin Beer Kabushiki Kaisha | Anti-TRAIL-R antibodies |
| US20050214209A1 (en) * | 2001-05-25 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| US20090226429A1 (en) * | 2001-05-25 | 2009-09-10 | Human Genome Sciences, Inc. | Antibodies That Immunospecifically Bind to TRAIL Receptors |
| US20050129616A1 (en) * | 2001-05-25 | 2005-06-16 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| US7361341B2 (en) | 2001-05-25 | 2008-04-22 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors |
| US7348003B2 (en) | 2001-05-25 | 2008-03-25 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors |
| US7064189B2 (en) | 2001-05-25 | 2006-06-20 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| CN100506284C (zh) | 2001-10-19 | 2009-07-01 | 脉管生物生长有限公司 | 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法 |
| IL161686A0 (en) * | 2001-11-01 | 2004-09-27 | Uab Research Foundation | Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| ES2357225T3 (es) * | 2001-11-01 | 2011-04-20 | Uab Research Foundation | Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos. |
| AU2002361784A1 (en) * | 2001-12-20 | 2003-07-09 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| US20050069549A1 (en) | 2002-01-14 | 2005-03-31 | William Herman | Targeted ligands |
| DE10210427A1 (de) * | 2002-03-09 | 2003-10-09 | Hans Konrad Mueller-Hermelink | Humaner monoklonaler Antikörper |
| EP1521776A2 (en) * | 2002-07-04 | 2005-04-13 | Oncomab Gmbh | Neoplasm specific antibodies and uses thereof |
| KR20090046973A (ko) * | 2002-11-27 | 2009-05-11 | 아이알엠 엘엘씨 | 암세포에서 세포자멸사를 유도하기 위한 방법 및 조성물 |
| AU2008201431B2 (en) * | 2002-11-27 | 2011-11-24 | Irm, Llc | Methods and compositions for inducing Apoptosis in cancer cells |
| DE10311248A1 (de) | 2003-03-14 | 2004-09-30 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Humaner monoklonaler Antikörper |
| EP1531162A1 (en) | 2003-11-14 | 2005-05-18 | Heinz Vollmers | Adenocarcinoma specific antibody SAM-6, and uses thereof |
| DE10353175A1 (de) | 2003-11-14 | 2005-06-16 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Humaner monoklonaler Antikörper mit fettsenkender Wirkung |
| KR20060132006A (ko) | 2004-03-23 | 2006-12-20 | 비오겐 아이덱 엠에이 아이엔씨. | 수용체 커플링제 및 이의 치료적 용도 |
| CN100427505C (zh) * | 2004-08-19 | 2008-10-22 | 中国医学科学院基础医学研究所 | 抗人肿瘤坏死因子相关凋亡诱导配体的受体dr5单克隆抗体（ad5-10）及其制法与用途 |
| BRPI0519008A2 (pt) * | 2004-12-13 | 2008-12-23 | Evogenix Ltd | proteÍnas variantes de osteoprotegerina |
| JP5562521B2 (ja) | 2005-02-02 | 2014-07-30 | ザ ユーエービー リサーチ ファンデーション | アポトーシス誘導デスレセプターアゴニストに対する抵抗性を低減することに関する薬剤及び方法 |
| US8029783B2 (en) | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
| JP5004154B2 (ja) * | 2005-04-06 | 2012-08-22 | 一般財団法人化学及血清療法研究所 | 組換え抗ボツリヌス神経毒素抗体 |
| EP1907001B1 (en) | 2005-06-17 | 2015-07-15 | Merck Sharp & Dohme Corp. | Ilt3 binding molecules and uses therefor |
| PE20071101A1 (es) * | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| UA97096C2 (ru) * | 2005-08-31 | 2012-01-10 | Емджен Інк. | Выделенное антитело, которое специфически связывает рецептор-2 trail (tr-2) |
| US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| AU2007250735A1 (en) | 2006-05-16 | 2007-11-22 | Daiichi Sankyo Company, Limited | Method for high-level secretory production of protein |
| CA2655903A1 (en) * | 2006-06-19 | 2008-08-07 | Tolerx, Inc. | Ilt3 binding molecules and uses therefor |
| KR100847010B1 (ko) * | 2006-07-05 | 2008-07-17 | 아주대학교산학협력단 | 세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물 |
| KR100804126B1 (ko) | 2007-02-09 | 2008-02-19 | 아주대학교산학협력단 | 종양 괴사 인자―관련 세포사멸―유도 리간드의 수용체에특이적으로 결합하는 1가의 인간 단일클론 항체 및 그의항원결합 단편 |
| AR066913A1 (es) * | 2007-06-08 | 2009-09-23 | Irm Llc | Metodos y composiciones para inducir la apoptosis en celulas cancerosas |
| CA2695991A1 (en) * | 2007-08-09 | 2009-02-12 | Daiichi Sankyo Company, Limited | Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor |
| ES2537806T5 (es) | 2007-10-31 | 2018-10-09 | Daiichi Sankyo Company, Limited | Método para la secreción y producción de alto nivel de proteína |
| WO2010047509A2 (ko) * | 2008-10-24 | 2010-04-29 | 아주대학교 산학협력단 | 친화도와 안정성이 향상된 항 ｄｒ5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물 |
| JP2013505944A (ja) * | 2009-09-24 | 2013-02-21 | シアトル ジェネティックス， インコーポレイテッド | Ｄｒ５リガンド薬物結合体 |
| EP2492281B1 (en) * | 2009-10-19 | 2018-04-11 | HanAll Biopharma Co., Ltd. | Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same |
| CA2780130A1 (en) | 2009-11-05 | 2011-05-12 | The Uab Research Foundation | Treating basal-like genotype cancers |
| US9238069B2 (en) | 2009-12-16 | 2016-01-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment |
| US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
| US9284350B2 (en) | 2010-02-12 | 2016-03-15 | Pharmascience Inc. | IAP BIR domain binding compounds |
| US8703712B2 (en) | 2010-03-18 | 2014-04-22 | The Uab Research Foundation | Targeting cancer stem cells with DR5 agonists |
| PH12013500845A1 (en) * | 2010-10-29 | 2013-06-24 | Daiichi Sankyo Co Ltd | Novel anti-dr5 antibody |
| CN103561771B (zh) | 2011-03-17 | 2019-01-04 | 伯明翰大学 | 重新定向的免疫治疗 |
| EP2704735A1 (en) * | 2011-05-03 | 2014-03-12 | Genentech, Inc. | Vascular disruption agents and uses thereof |
| HK1210192A1 (en) | 2012-07-19 | 2016-04-15 | Alethia Biotherapeutics Inc. | Anti-siglec-15 antibodies |
| NZ630363A (en) * | 2012-07-25 | 2018-09-28 | Celldex Therapeutics Inc | Anti-kit antibodies and uses thereof |
| CN103074425B (zh) * | 2012-12-29 | 2014-01-01 | 深圳市第三人民医院 | Cd263基因的用途 |
| WO2015051159A1 (en) * | 2013-10-02 | 2015-04-09 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
| CN104710533A (zh) * | 2013-12-12 | 2015-06-17 | 中国科学院深圳先进技术研究院 | sDR5-Fc融合蛋白及其用途 |
| IL308212A (en) | 2015-01-20 | 2024-01-01 | Igm Biosciences Inc | Tumor necrosis factor-α receptor binding molecules and their uses |
| RU2017129236A (ru) | 2015-01-26 | 2019-03-07 | Макродженикс, Инк. | Мультивалентные молекулы, содержащие dr5-связывающие домены |
| CN105061604B (zh) * | 2015-08-19 | 2018-03-16 | 河南大学 | sDR5‑Fc融合蛋白突变体及其应用 |
| CN109195626B (zh) | 2015-10-30 | 2022-09-13 | 银河生物技术有限责任公司 | 结合死亡受体4和死亡受体5的抗体 |
| CN109476737A (zh) | 2015-12-01 | 2019-03-15 | 根马布有限公司 | 抗dr5抗体及其使用方法 |
| CN106924735A (zh) * | 2015-12-29 | 2017-07-07 | 上海交通大学医学院附属瑞金医院 | 多巴胺1类受体激动剂在制备肿瘤治疗药物中的用途 |
| US10849912B2 (en) | 2016-02-09 | 2020-12-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment |
| CA3015619A1 (en) | 2016-03-01 | 2017-09-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human poliovirus receptor (pvr) |
| KR101926166B1 (ko) * | 2016-05-24 | 2018-12-06 | 재단법인 아산사회복지재단 | 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법 |
| US11680101B2 (en) | 2017-01-27 | 2023-06-20 | Kymab Limited | Anti-OPG antibodies |
| KR101926834B1 (ko) * | 2017-03-21 | 2018-12-07 | 동아에스티 주식회사 | 항-dr5 항체 및 그의 용도 |
| EP3635005A1 (en) | 2017-06-07 | 2020-04-15 | Genmab B.V. | Therapeutic antibodies based on mutated igg hexamers |
| KR101951025B1 (ko) | 2017-08-17 | 2019-02-21 | 서울대학교산학협력단 | 세포사멸 수용체 저해제를 유효성분으로 포함하는 cx3cl1 케모카인 과발현으로 인한 질환 예방 또는 치료용 조성물 |
| EP3684409A4 (en) * | 2017-09-22 | 2021-06-23 | Immunogen, Inc. | SEPARATION OF TRIPLE LIGHT CHAIN ANTIBODIES USING CATION EXCHANGE CHROMATOGRAPHY |
| WO2019100194A1 (zh) * | 2017-11-21 | 2019-05-31 | 深圳先进技术研究院 | 抗dr5的抗体及其制备方法和应用 |
| WO2019100193A1 (zh) * | 2017-11-21 | 2019-05-31 | 深圳先进技术研究院 | 抗dr5的抗体及其制备方法和应用 |
| CN108251443A (zh) * | 2018-01-23 | 2018-07-06 | 深圳市人民医院 | 一种tnfrsf10c重组质粒、制备方法及其应用 |
| US12018045B2 (en) | 2018-03-06 | 2024-06-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | 17-beta-hydroxywithanolides and use thereof in treating cancer |
| CN117126279A (zh) | 2018-03-20 | 2023-11-28 | 鸿运华宁（杭州）生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| EP3897851A2 (en) | 2018-12-17 | 2021-10-27 | Revitope Limited | Twin immune cell engager |
| EP4041392A1 (en) | 2019-10-08 | 2022-08-17 | Nectin Therapeutics Ltd. | Antibodies against the poliovirus receptor (pvr) and uses thereof |
| EP4277706A1 (en) | 2021-01-15 | 2023-11-22 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB9028123D0 (en) * | 1990-12-28 | 1991-02-13 | Erba Carlo Spa | Monoclonal antibodies against human tumor necrosis factor alpha |
| US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
| US6433147B1 (en) * | 1997-01-28 | 2002-08-13 | Human Genome Sciences, Inc. | Death domain containing receptor-4 |
| PT1012274E (pt) | 1997-01-28 | 2007-08-14 | Craig A Rosen | Receptor 4 contendo um domínio de morte (dm4; receptor de morte 4), membro da super-família do ftn e ligação a liart (ap02) |
| US6072047A (en) * | 1997-02-13 | 2000-06-06 | Immunex Corporation | Receptor that binds trail |
| US6313269B1 (en) * | 1997-03-14 | 2001-11-06 | Smithkline Beecham Corporation | Tumor necrosis factor related receptor, TR6 |
| JP4330180B2 (ja) | 1997-03-17 | 2009-09-16 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | 死ドメイン含有レセプター５ |
| US6872568B1 (en) * | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
| IL123888A0 (en) | 1997-04-01 | 1998-10-30 | Sankyo Co | Anti-fas antibodies |
| AU7126498A (en) | 1997-04-16 | 1998-11-11 | Millennium Pharmaceuticals, Inc. | Tumor necrosis factor receptor related proteins tango-63d and tango-63e |
| US6342369B1 (en) * | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
| ES2293682T5 (es) | 1997-05-15 | 2011-11-17 | Genentech, Inc. | Anticuerpo anti-apo2. |
| AU8400398A (en) | 1997-07-11 | 1999-02-08 | Trustees Of The University Of Pennsylvania, The | Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use |
| EP0998561A4 (en) * | 1997-07-15 | 2004-08-18 | Immunex Corp | RECEPTOR DES TRAIL PROTEIN |
| AU3710597A (en) | 1997-08-06 | 1999-03-01 | Laboratorio Medinfar-Produtos Farmaceuticos, Lda | Dna integration into "mycobacterium spp." genome by trans-complementation using a site-specific integration system |
| ATE233887T1 (de) * | 1997-08-13 | 2003-03-15 | Sortech Ag | Sorptionsspeicher, anordnung und verfahren zur speicherung von wärme |
| CA2301202A1 (en) * | 1997-08-15 | 1999-02-25 | Idun Pharmaceuticals, Inc. | Trail receptors, nucleic acids encoding the same, and methods of use thereof |
| WO1999011791A2 (en) | 1997-09-05 | 1999-03-11 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
| CA2301173C (en) | 1997-09-12 | 2015-04-14 | Biogen, Inc. | Cysteine rich receptors-train |
| US7105640B2 (en) * | 1997-10-17 | 2006-09-12 | Genentech, Inc. | Anti-pro792 antibodies |
| AU2338299A (en) | 1998-01-26 | 1999-08-09 | Genentech Inc. | Antibodies to death receptor 4 (dr4) and uses thereof |
| US20040120947A1 (en) | 1998-01-26 | 2004-06-24 | Genentech, Inc. | DR4 antibodies and uses thereof |
| US6252050B1 (en) * | 1998-06-12 | 2001-06-26 | Genentech, Inc. | Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method |
| CA2365913C (en) * | 1999-04-12 | 2015-03-03 | Genentech, Inc. | Tumor necrosis factor receptor homologs and nucleic acids encoding the same |
| JP2002543151A (ja) | 1999-05-04 | 2002-12-17 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | 死ドメイン含有レセプター５ |
| CA2373063A1 (en) | 1999-05-06 | 2000-11-16 | Jian Ni | Death domain containing receptor 4 |
| EP1181319B1 (en) | 1999-05-28 | 2009-04-22 | Genentech, Inc. | Chimeric dr4 antibodies and uses thereof |
| ATE330972T1 (de) | 1999-06-09 | 2006-07-15 | Genentech Inc | Apo-2l rezeptor-agonist und cpt-11 synergie- effekt |
| US6294546B1 (en) | 1999-08-30 | 2001-09-25 | The Broad Of Trustees Of The Leland Stanford Junior University | Uses of diterpenoid triepoxides as an anti-proliferative agent |
| CA2384762A1 (en) | 1999-09-15 | 2001-03-22 | Genentech, Inc. | Apo-2 receptor antibodies |
| JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
| US7476383B2 (en) * | 2000-05-02 | 2009-01-13 | The Uab Research Foundation | Antibody selective for DR4 and uses thereof |
| TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| US7279160B2 (en) * | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
| WO2002079377A2 (en) | 2000-11-08 | 2002-10-10 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| US20030228309A1 (en) * | 2000-11-08 | 2003-12-11 | Theodora Salcedo | Antibodies that immunospecifically bind to TRAIL receptors |
| US6965023B2 (en) * | 2000-11-17 | 2005-11-15 | The Burnham Institute | Death domain proteins |
| EP1409544B1 (en) | 2001-07-03 | 2009-06-17 | Genentech, Inc. | Human dr4 antibodies and uses thereof |
| ES2357225T3 (es) | 2001-11-01 | 2011-04-20 | Uab Research Foundation | Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos. |
| IL161686A0 (en) | 2001-11-01 | 2004-09-27 | Uab Research Foundation | Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
-
2001
- 2001-05-01 TW TW090110398A patent/TWI318983B/zh not_active IP Right Cessation
- 2001-05-02 WO PCT/US2001/014151 patent/WO2001083560A1/en not_active Ceased
- 2001-05-02 US US10/275,180 patent/US7244429B2/en not_active Expired - Lifetime
- 2001-05-02 DE DE60138097T patent/DE60138097D1/de not_active Expired - Lifetime
- 2001-05-02 CA CA2407965A patent/CA2407965C/en not_active Expired - Lifetime
- 2001-05-02 CZ CZ2006-291A patent/CZ306996B6/cs not_active IP Right Cessation
- 2001-05-02 EP EP08021291.3A patent/EP2065400B1/en not_active Expired - Lifetime
- 2001-05-02 KR KR1020027014707A patent/KR100817967B1/ko not_active Expired - Lifetime
- 2001-05-02 PT PT01932876T patent/PT1287035E/pt unknown
- 2001-05-02 HU HU0500800A patent/HU230399B1/hu unknown
- 2001-05-02 EP EP08021292.1A patent/EP2065401B1/en not_active Expired - Lifetime
- 2001-05-02 CN CN200910137028.9A patent/CN101585881B/zh not_active Expired - Lifetime
- 2001-05-02 AU AU2001259366A patent/AU2001259366B2/en not_active Expired
- 2001-05-02 ES ES01932876T patent/ES2323448T3/es not_active Expired - Lifetime
- 2001-05-02 EP EP10011253.1A patent/EP2368910B1/en not_active Expired - Lifetime
- 2001-05-02 CZ CZ2002-3917A patent/CZ304614B6/cs not_active IP Right Cessation
- 2001-05-02 CN CNB018120385A patent/CN100497388C/zh not_active Expired - Lifetime
- 2001-05-02 AU AU5936601A patent/AU5936601A/xx active Pending
- 2001-05-02 NZ NZ522881A patent/NZ522881A/en not_active IP Right Cessation
- 2001-05-02 DK DK01932876T patent/DK1287035T3/da active
- 2001-05-02 EP EP01932876A patent/EP1287035B1/en not_active Expired - Lifetime
- 2001-05-02 RU RU2002132255/13A patent/RU2298013C2/ru active
- 2001-05-02 JP JP2001580185A patent/JP4156238B2/ja not_active Expired - Lifetime
- 2001-05-02 EE EEP200200621A patent/EE05548B1/xx unknown
- 2001-05-02 AT AT01932876T patent/ATE426615T1/de active
- 2001-05-02 PL PL366195A patent/PL211733B1/pl not_active IP Right Cessation
- 2001-05-02 BR BR0110547-7A patent/BR0110547A/pt not_active Application Discontinuation
- 2001-05-02 IL IL15260501A patent/IL152605A0/xx active IP Right Grant
- 2001-05-02 KR KR1020067015043A patent/KR20060092292A/ko not_active Ceased
- 2001-05-02 HU HU0400951A patent/HU229417B1/hu not_active IP Right Cessation
- 2001-05-02 MX MXPA02010823A patent/MXPA02010823A/es active IP Right Grant
-
2002
- 2002-11-01 NO NO20025253A patent/NO329843B1/no not_active IP Right Cessation
- 2002-11-13 ZA ZA200209230A patent/ZA200209230B/en unknown
- 2002-11-14 BG BG109275A patent/BG109275A/en unknown
- 2002-11-14 BG BG107275A patent/BG65929B1/bg unknown
-
2005
- 2005-04-11 JP JP2005113535A patent/JP3892466B2/ja not_active Expired - Lifetime
- 2005-08-23 BG BG109275A patent/BG66153B1/bg unknown
- 2005-09-06 NO NO20054145A patent/NO338228B1/no not_active IP Right Cessation
-
2006
- 2006-11-22 JP JP2006315093A patent/JP2007091749A/ja active Pending
-
2007
- 2007-06-08 US US11/760,491 patent/US7790165B2/en not_active Expired - Fee Related
-
2008
- 2008-07-29 JP JP2008194948A patent/JP4575975B2/ja not_active Expired - Lifetime
-
2009
- 2009-06-24 CY CY20091100656T patent/CY1109179T1/el unknown
-
2010
- 2010-06-24 US US12/822,732 patent/US8067001B2/en not_active Expired - Fee Related
-
2011
- 2011-10-10 US US13/269,811 patent/US8329180B2/en not_active Expired - Fee Related
-
2012
- 2012-09-17 US US13/621,383 patent/US8715668B2/en not_active Expired - Fee Related
-
2014
- 2014-03-12 US US14/206,797 patent/US9700618B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004502409A5 (2) | ||
| JP2004531270A5 (2) | ||
| JP2008529529A5 (2) | ||
| JP2007532098A5 (2) | ||
| JP2010533498A5 (2) | ||
| JP2011510654A5 (2) | ||
| CN115461368A (zh) | 抗人白细胞介素-4受体α抗体及其制备方法和应用 | |
| JP2020525032A5 (2) | ||
| JP2023093753A5 (2) | ||
| JP2022506719A5 (2) | ||
| JP2022523442A5 (2) | ||
| RU2011116927A (ru) | Антитела против интерлейкина 17 (ил-17) человека и их применение | |
| JP2010532764A5 (2) | ||
| JP2008511291A5 (2) | ||
| JP2008516970A5 (2) | ||
| JP2014518615A5 (2) | ||
| JP2006025793A5 (2) | ||
| JP2003503017A5 (2) | ||
| JP2002503495A5 (2) | ||
| JP2012501669A5 (2) | ||
| US11597763B2 (en) | Anti-Kv1.3 antibodies, and methods of production and use thereof | |
| JP2024095774A5 (2) | ||
| JP2024516098A5 (2) | ||
| JP2020515277A5 (2) | ||
| JP2003527078A5 (2) |